(Reuters) -Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business, marking the second multi-billion dollar deal struck by the drugmaker ...

Radiopharmaceutical drugmaker RayzeBio drew interest from two other large drugmakers before agreeing to a $4.1 billion buyout by Bristol Myers Squibb, newly published documents show. The companies, ...

The company, which is owned by biopharmaceutical giant Bristol Myers Squibb Co., is working on an incentive package with Whitestown officials that includes tax abatements for construction and new ...

RayzeBio and Neumora Therapeutics have joined the public markets, and in contrast to the plethora of preclinical biotech IPOs of 2020 and 2021, these two Wall Street newcomers each have multiple drug ...

EDMONTON, Alberta & SAN DIEGO, Calif.--(BUSINESS WIRE)--48Hour Discovery Inc and RayzeBio today announced the companies have entered a strategic research collaboration to discover and develop novel ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Neumora and RayzeBio are both casting a line into the market, with each seeking to raise more than $200 million in initial public offerings this fall. Neumora is offering 14,710,000 shares at a range ...

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Christy Oliger to its board of ...

It may have been a day late, but Bristol Myers Squibb (BMY -2%) gave RayzeBio (RYZB +101%) investors a nice stocking stuffer today. BMY will acquire RayzeBio for $62.50 per share in cash, for a total ...

RayzeBio Inc, a San Diego company focused on radiopharmaceutical therapies for cancer, filed on Thursday to raise up to $100 million in an initial public offering. The phase 3-stage company was ...

RayzeBio (RYZB), a Phase 3 biotech developing radiopharmaceutical therapies for cancer has priced its upsized $311 million initial public offering of 17.28 million shares of common stock at a price to ...